SYRACUSE, N.Y.--(BUSINESS WIRE)--Central New York Biotech Accelerator (CNYBAC) — Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing breakthrough therapies, via local administration, for metastatic breast cancer to bone and soft tissues, announced today that the first two patients have enrolled in the phase 2a study, which will evaluate ZetaMet™ (Zeta-BC-003) in the treatment of spinal metastatic lytic breast cancer lesions (ClinicalTrials.gov #NCT05280067)..

纽约州锡拉丘兹市（商业新闻短讯）--纽约中央生物技术加速器（CNYBAC）-Zetagen Therapeutics，Inc.，一家私营的临床阶段生物制药公司，专注于通过当地管理开发突破性疗法，治疗转移性乳腺癌骨和软组织，今天宣布前两名患者已参加2a期研究，该研究将评估ZetaMet™（Zeta-BC-003）治疗脊柱转移性溶解性乳腺癌病变（ClinicalTrials.gov#NCT05280067）。。

“Our discovery is the first of its kind with the potential to be a curative therapy for this high unmet need,” stated Joe C. Loy, CEO of Zetagen. “Our vision is to deliver breakthrough therapies to all individuals affected by metastatic breast cancer, offering them pain relief, a higher quality of life, while increasing survival rates.

Zetagen首席执行官乔·洛伊（JoeC.Loy）表示：“我们的发现是此类发现中的第一个，有可能成为这种高度未满足需求的治疗方法。”。“我们的愿景是为所有受转移性乳腺癌影响的个体提供突破性治疗，为他们缓解疼痛，提高生活质量，同时提高生存率。

The commencement of this study represents a major milestone in the development of ZetaMet™(Zeta-BC-003) and brings us closer to turning our vision into reality.”.

这项研究的开始代表了ZetaMet™（Zeta-BC-003）开发的一个重要里程碑，使我们更接近将愿景变为现实。”。

The 26-week study, conducted at the University of British Columbia, (UBC) Vancouver, BC, Canada, will evaluate the safety and efficacy of ZetaMet™ (Zeta-BC-003) in treating vertebral bone defects created by lytic metastatic breast cancer. The study will measure the reduction of skeletal related events (SRE), pain, change in vertebral body defect size, and postoperative prescription opioid use..

这项为期26周的研究在加拿大不列颠哥伦比亚大学（UBC）温哥华进行，将评估ZetaMet™（Zeta-BC-003）治疗溶解性转移性乳腺癌引起的椎骨缺损的安全性和有效性。该研究将测量骨骼相关事件（SRE）的减少，疼痛，椎体缺损大小的变化以及术后处方阿片类药物的使用。。

About ZetaMet™ (Zeta-BC-003)

关于ZetaMet™（Zeta-BC-003）

ZetaMet™ (Zeta-BC-003) is a synthetic, small-molecule, delivered via a proprietary controlled-release carrier intended to resolve metastatic breast cancer bone lesions, inhibit pain while regenerating bone, with the potential to increase survival rates.

ZetaMet™（Zeta-BC-003）是一种合成的小分子，通过专有的控释载体递送，旨在解决转移性乳腺癌骨病变，抑制疼痛，同时再生骨骼，并有可能提高存活率。

ZetaMet’s (Zeta-BC-003) small molecule mechanism of action (MOA) via a novel molecular pathway initiates a circuit which results in tumor cell death.

ZetaMet（Zeta-BC-003）的小分子作用机制（MOA）通过一种新的分子途径启动了一个导致肿瘤细胞死亡的电路。

The US Food & Drug Administration (FDA) has recognized Zetagen’s discoveries with multiple Breakthrough Designations including ZetaMet™ (Zeta-BC-003).

美国食品和药物管理局（FDA）已经认可了Zetagen的发现，包括ZetaMet™（Zeta-BC-003）在内的多个突破性名称。

Zetagen with FDA approval via the Expanded Access (Compassionate Use) program has treated several patients with ZetaMet™ (Zeta-BC-003) with results published in multiple peer-reviewed journals.

Zetagen通过扩展访问（同情使用）计划获得FDA批准，治疗了几名ZetaMet™（Zeta-BC-003）患者，结果发表在多个同行评审期刊上。

Peer-reviewed 2-year follow up clinical data published in 2023 on ZetaMet™ (Zeta-BC-003) demonstrated resolution of 7 lytic lesions (radiated and non-radiated), reduction in pain, significant attrition of opioid pain medication (4-fold), prevention of vertebral fracture, and increased survival rate in a patient living with Stage 4 breast cancer.i To view this publication via open access, go to: https://www.tandfonline.com/doi/full/10.2217/pmt-2023-0069.

2023年发表在ZetaMet™（Zeta-BC-003）上的同行评审的2年随访临床数据显示，7个溶解性病变（辐射和非辐射）得以解决，疼痛减轻，阿片类止痛药明显消耗（4倍），预防椎骨骨折，并提高了4期乳腺癌患者的生存率。要通过开放获取查看本出版物，请访问：https://www.tandfonline.com/doi/full/10.2217/pmt-2023-0069.

About Zetagen Therapeutics

关于Zetagen Therapeutics

Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for metastatic breast cancer to bone and soft tissues which may provide increased survival rates.

Zetagen Therapeutics成立于2015年，是一家私营的临床阶段生物制药公司，致力于通过局部给药开发突破性疗法，治疗转移性乳腺癌至骨骼和软组织，从而提高生存率。

The company's ‘Zeta” platform encompasses the following oncological drug candidates ZetaMet™ (Zeta-BC-003), ZetaMet-P™ (Zeta-PC-004) and ZetaMAST™ (Zeta-MBC-005). To learn more, visit www.zetagen.com

该公司的“Zeta”平台包括以下肿瘤候选药物ZetaMet™（Zeta-BC-003），ZetaMet-P™（Zeta-PC-004）和ZetaMAST™（Zeta-MBC-005）。要了解更多信息，请访问www.zetagen.com

Zetagen will attend the upcoming San Antonio Breast Cancer Symposium (SABCS) and the JP Morgan Healthcare Conference.

泽塔根将出席即将举行的圣安东尼奥乳腺癌研讨会（SABCS）和摩根大通医疗保健会议。

Forward-Looking Statements

前瞻性声明

This press release contains certain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature.

本新闻稿包含1933年《证券法》第27A节、1934年《证券交易法》第21E节和经修订的《私人证券诉讼改革法》所指的某些前瞻性声明，包括与公司产品开发、临床和监管时间表、市场机会、竞争地位、可能或假定的未来经营成果、业务战略、潜在增长机会和其他具有预测性质的声明有关的前瞻性声明。

These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions..

这些前瞻性陈述基于对我们经营的行业和市场的当前预期、估计、预测和预测以及管理层当前的信念和假设。。

i Pain Management. Volume 13, Issue 10, October 2023, Pages 569-577 https://doi.org/10.2217/pmt-2023-0069

我疼痛管理。第13卷第10期，2023年10月，第569-577页https://doi.org/10.2217/pmt-2023-0069